Advanced search
Publication Cover
Orbit
The International Journal on Orbital Disorders, Oculoplastic and Lacrimal Surgery
Volume 43, 2024 - Issue 3
Submit an article Journal homepage
117
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Change in upper eyelid position after teprotumumab treatment for thyroid eye disease

Tatiana R. RosenblattDepartment of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1694-405XView further author information
ORCID Icon,
Carolina A. ChiouDepartment of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USAORCID Iconhttps://orcid.org/0000-0002-0169-9429View further author information
ORCID Icon,
Michael K. YoonDepartment of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USAView further author information
,
Nahyoung Grace LeeDepartment of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USAView further author information
,
Natalie WolkowDepartment of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USAView further author information
&
Suzanne K. FreitagDepartment of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USAView further author information
Pages 337-343 | Received 23 Dec 2023, Accepted 20 Feb 2024, Published online: 11 Mar 2024

References

  • Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121(3):284–290. doi:10.1016/S0002-9394(14)70276-4.
  • Bahn RS. Mechanisms of disease: Graves’ ophthalmopathy. N Engl J Med. 2010;362(8):726–738. doi:10.1056/NEJMra0905750.
  • Weetman AP. Thyroid-associated eye disease: pathophysiology. Lancet. 1991;338:25–28.
  • Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748–1761. doi:10.1056/NEJMoa1614949.
  • Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341–52. doi:10.1056/NEJMoa1910434.
  • Ting M, Ezra DG. Teprotumumab: a disease modifying treatment for graves’ orbitopathy. Thyroid Res. 2020;13(1):12–12. doi:10.1186/s13044-020-00086-7.
  • Douglas RS, Dailey R, Subramanian PS, et al. Proptosis and diplopia response with teprotumumab and placebo vs the recommended treatment regimen with intravenous methylprednisolone in moderate to severe thyroid eye disease. JAMA Ophthalmol. 2022;140(4):328–335. doi:10.1001/jamaophthalmol.2021.6284.
  • Douglas RS. Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis. Eye. 2019;33(2):183–190. doi:10.1038/s41433-018-0321-y.
  • Rosenblatt TR, Chiou CA, Yoon MK, Wolkow N, Lee NG, Freitag SK. Proptosis regression after teprotumumab for thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2023;10:1097. doi:10.1097/IOP.0000000000002531.
  • Simmons BA, Tran C, Pham CM, Shriver EM. The effect of teprotumumab on eyelid position in patients with thyroid eye disease. Plast Reconstr Surg Glob Open. 2022;10(4):e4287. doi:10.1097/GOX.0000000000004287.
  • Ozzello DJ, Dallalzadeh LO, Liu CY. Teprotumumab for chronic thyroid eye disease. Orbit (Amsterdam). 2022;41(5):539–546. doi:10.1080/01676830.2021.1933081.
  • Diniz SB, Cohen LM, Roelofs KA, Rootman DB. Early experience with the clinical use of teprotumumab in a heterogeneous thyroid eye disease population. Ophthalmic Plast Reconstr Surg. 2021;37(6):583–591. doi:10.1097/IOP.0000000000001959.
  • Ho TC, Maamari RN, Kossler AL, et al. Outcomes of patients with thyroid eye disease partially treated with teprotumumab. Ophthalmic Plast Reconstr Surg. 2023;39(2):150–155. doi:10.1097/IOP.0000000000002267.
  • Ugradar S, Braun J, Wang Y, Zimmerman E, Douglas RS. Facial and eyelid changes in thyroid eye disease are reversed by teprotumumab. Plast Reconstr Surg Globe Open. 2021;9(9):e3809. doi:10.1097/GOX.0000000000003809.
  • Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid. 2008;18:333–346. doi:10.1089/thy.2007.0315.
  • Osaki TH, Monteiro LG, Osaki MH. Management of eyelid retraction related to thyroid eye disease. Taiwan J Ophthalmol. 2022;12(1):12–21. doi:10.4103/tjo.tjo_57_21.
  • Cruz AAV, Ribeiro SFT, Garcia DM, Akaishi PM, Pinto CT. Graves upper eyelid retraction. Surv Ophthalmol. 2013;58(1):63–76. doi:10.1016/j.survophthal.2012.02.007.
  • Rootman DB, Golan S, Pavlovich P, Rootman J. Postoperative changes in strabismus, ductions, exophthalmometry, and eyelid retraction after orbital decompression for thyroid orbitopathy. Ophthalmic Plast Reconstr Surg. 2017;33(4):289–293. doi:10.1097/IOP.0000000000000758.
  • Rajabi MT, Jafari H, Mazloumi M, et al. Lower lid retraction in thyroid orbitopathy: lamellar shortening or proptosis? Int Ophthalmol. 2014;34(4):801–804. doi:10.1007/s10792-013-9877-5.
  • Cockerham KP, Hidayat AA, Brown HG, Cockerham GC, Graner SR. Clinicopathologic evaluation of the Mueller muscle in thyroid-associated orbitopathy. Ophthal Plast Reconstr Surg. 2022;18(1):11–17. doi:10.1097/00002341-200201000-00003.
  • Chen H, Mester T, Raychaudhuri N, et al. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab. 2014;99(9):e1635–1640. doi:10.1210/jc.2014-1580.
  • Lee DC, Young SM, Kim Y, Woo KI. Course of upper eyelid retraction in thyroid eye disease. Br J Ophthalmol. 2020;104(2):254–259. doi:10.1136/bjophthalmol-2018-313578.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.